This study looks at inotuzumab ozogamicin, a special medicine for young patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia. These are types of blood cancer that have returned or don’t respond to regular treatment. Inotuzumab ozogamicin is a monoclonal antibody, which is like a special marker that attaches to cancer cells with a CD22 marker. It carries a toxin to kill the cancer cells.
In the study, patients are divided into two groups. The first group (Cohort I) will receive inotuzumab ozogamicin through an IV (a tube into a vein) for 60 minutes on certain days, up to 6 cycles. The second group (Cohort II) gets inotuzumab ozogamicin plus other drugs. Patients will have tests like blood tests and scans during the study.
Key Points:
- The study could last for several months with cycles repeating every 28-42 days.
- Regular visits and tests are required to monitor the patient's health and cancer progression.
- There are risks, such as side effects from the drugs, which the study aims to understand better.